2023 World Conference on Lung Cancer (Posters)-EP12.01. The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastasess

EP12.01. The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastasess - PDF(Abstract)

Back to course

Pdf Summary

This document describes a study investigating the optimal timing of treatment for patients with metastatic non-small cell lung cancer (NSCLC) and multiple brain metastases. Brain metastases are a common occurrence in lung adenocarcinoma, and the best treatment approach is still debated. Current guidelines recommend local treatment for NSCLC patients with symptomatic brain metastases and stable extracranial lesions. For patients with 3 or more brain metastases, whole brain radiotherapy (WBRT) or stereotactic radiotherapy (SRT) can be used. However, WBRT has not been shown to improve overall survival and can cause short-term toxicities. Hypo-fractionated stereotactic radiotherapy (HFSRT) is being explored as an alternative, as it may reduce toxicity.<br /><br />The study aims to investigate the timing of third-generation tyrosine kinase inhibitors (TKIs) combined with radiotherapy to improve patient survival. The trial is a single-center prospective randomized controlled clinical trial that will enroll 100 patients with EGFR mutations. Patients will be randomly assigned to two cohorts. In cohort A, HFSRT will be administered first, followed by the TKI aumolertinib. In cohort B, aumolertinib will be given first, followed by radiotherapy. The primary endpoints of the study are intracranial progression-free survival and overall survival.<br /><br />The study will also assess objective response rate, disease control rate, adverse events of radiotherapy and aumolertinib, and the patients' quality of life. Patients will be followed up regularly for up to 5 years.<br /><br />This study aims to provide evidence on the optimal timing of treatment for EGFR-mutated NSCLC patients with multiple brain metastases. The results could help improve patient outcomes and guide clinical decision-making.

Asset Subtitle

Qian Shao

Meta Tag

Speaker Qian Shao

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

metastatic non-small cell lung cancer

multiple brain metastases

lung adenocarcinoma

optimal timing of treatment

local treatment

whole brain radiotherapy

stereotactic radiotherapy

hypo-fractionated stereotactic radiotherapy

tyrosine kinase inhibitors

EGFR mutations